Wed, Jul 23, 2014, 7:05 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Seattle Genetics Inc. Message Board

  • ricardouno ricardouno Dec 10, 2012 6:33 PM Flag

    More Adcetris Data From ASH

    Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting

    - 96 Percent Complete Remission Rate in Newly Diagnosed Hodgkin Lymphoma Patients Treated with ADCETRIS in Combination with AVD Chemotherapy -

    - Safety and Response Data Support Ongoing Phase III Trial of ADCETRIS and AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin Lymphoma -

    Ricardo says: "This drug is no humbug"

    Good luck to all !

 
SGEN
35.00+0.74(+2.16%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.